Venky's Starts Production At New Kesurdi Plant With ₹67 Crore Investment

Market snapshot: Venky's (India) Limited has operationalized its new manufacturing facility at Kesurdi in Satara district, Maharashtra, under its Animal Health Products segment. Built with an investment of ₹67 crore, the plant is designed to double division capacity and support an expected 15% to 20% expansion in product volumes.

Data Snapshot

• Total project capex of ₹67 crore allocated to the specialized Kesurdi manufacturing facility.
• Anticipated 15% to 20% volume growth in the Animal Health Products segment post-commissioning.
• Expansion doubles manufacturing capacity for veterinary medicine powders and liquids.

What's Changed

• Operationalization of the Kesurdi facility doubles the manufacturing capacity of the Animal Health Products division.
• The segment expands from single-plant operations toward scaling specialized therapeutics for domestic and international markets.

Key Takeaways

• Capacity Doubling: The ₹67 crore Kesurdi unit expands production infrastructure for veterinary medicine powders and liquids.
• Margin Buffer: Higher-margin Animal Health Products reduce corporate earnings dependency on volatile poultry feed raw material costs.
• Debt-Free Execution: Expansion was funded entirely through internal accruals, preserving zero term debt in the Animal Health segment.

SAHI Perspective

The commissioning of the Kesurdi plant marks a strategic pivot toward expanding Venky's higher-margin, non-commodity business. By scaling veterinary therapeutics without leverage, the company builds structural earnings stability against raw material input cycles.

Market Implications

Incremental revenue from the 15% to 20% volume growth target should boost segment profitability. Expanding the animal healthcare share within the total business mix provides stronger margin protection during downturns in poultry realization.

Trading Signals

Market Bias: Bullish

Commissioning of the self-funded ₹67 crore Kesurdi facility doubles capacity and supports 15% to 20% volume growth in high-margin animal healthcare products, enhancing medium-term margin resilience.

Overweight: Animal Healthcare, Poultry Value Chain

Trigger Factors:

• Capacity utilization ramp-up at Kesurdi plant
• Quarterly segment revenue and volume trajectory in Animal Health Products
• Raw material cost trends in soya and maize

Time Horizon: Medium-term (3-12 months)

Industry Context

India's animal health and veterinary products industry is benefiting from commercial farm modernization and enhanced biosecurity standard adoption. Expanding domestic manufacturing of specialized healthcare products allows producers to serve expanding livestock demand efficiently.

Key Risks to Watch

• Slower commercial ramp-up or delays in receiving international regulatory approvals.
• Severe raw material inflation in feed ingredients impacting primary poultry operations.

Recent Developments

Venky's completed construction and obtained regulatory permissions for its Kesurdi unit in Satara district, Maharashtra, establishing capacity for 600 tonnes per annum of veterinary medicine powders and 300 kilolitres per annum of liquids.

Closing Insight

Venky's disciplined, self-funded plant expansion strengthens its strategic footprint in animal healthcare, offering clear volume growth and margin diversification.

High Performance Trading with SAHI.